Project Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
177Lu-PSMA-617 abiraterone abiraterone acetate ADC ADT AI ai in healthcare antibody-drug conjugate apalutamide ATM B7-H3 bispecific antibody bone metastases bone metastasis BRCA BRCA2 cancer immunotherapy CAR-T clinical trial crispr darolutamide docetaxel drug repurposing drug resistance enzalutamide EZH2 inhibitor HRR immunotherapy mcrpc metastatic hormone-sensitive prostate cancer mHSPC mRNA NEPC neuroendocrine prostate cancer oncolytic virus PARP inhibitor Pluvicto prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data T-cell therapy theranostics
Latest Posts
- Newsletter 11/2026 March 15, 2026
- Blood Lipid Profiles in Metastatic Prostate Cancer: A Window into Tumor Metabolism and Response to Enzalutamide March 14, 2026
- Organoids from Routine TUR‑P Samples: A Personalized Platform for Prostate Cancer Therapy Testing March 13, 2026
- Estrogen‑Based Androgen Suppression Plus ARSI in Prostate Cancer: A Phase 2 Quality‑of‑Life Trial March 13, 2026

TJ101 Enters Testing for Advanced Prostate Cancer Patients
/in Clinical Trial, Metastatic, Phase 1/by MaxSpanish Study Confirms Real-World Success of Apalutamide in Prostate Cancer
/in Retrospective studies/by MaxFrom Proteins to Pathways: PDGrapher’s Shift in Drug Discovery
/in Artificial Intelligence/by MaxOST-504: A Novel Immunotherapy Targeting Prostate Cancer
/in Clinical Trial, Metastatic, Phase 1/by MaxMemantine Shows Promise Against Advanced Prostate Cancer
/in Clinical Trial, Metastatic, Phase 2/by MaxPasritamig in Late-Line Prostate Cancer: From Early Findings to the KLK2-comPAS Trial
/in Clinical Trial, Metastatic, Phase 3/by MaxFDA Clears First Therapeutic Trial of Lead-212 Radioligand AB001 in Prostate Cancer
/in Clinical Trial, Metastatic, Phase 1/by MaxUPDATE: Phase 2 Results for 177Lu-DGUL Look Very Promising
/in Clinical Trial, Metastatic, Phase 2/by Max